Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Biosimilar filgrastim (Zarzio) treatment patterns and relative dose intensity maintenance in patients receiving chemotherapy for the treatment of solid tumour or lymphoid malignancies

Next Previous
Trial Profile

Biosimilar filgrastim (Zarzio) treatment patterns and relative dose intensity maintenance in patients receiving chemotherapy for the treatment of solid tumour or lymphoid malignancies

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Acronyms ZOHe

Most Recent Events

  • 02 Jul 2015 New trial record
  • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
  • 02 Jun 2015 Patients were recruited between June 2013 and April 2014, according results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top